HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Histone deacetylase inhibitors down-regulate G-protein-coupled estrogen receptor and the GPER-antagonist G-15 inhibits proliferation in endometriotic cells.

AbstractOBJECTIVE:
To investigate whether histone deacetylase inhibitors reduce the expression of the G-protein-coupled estrogen receptor (GPER) and whether the functional inhibition of GPER by the antagonist G-15 decreases the proliferation of endometriotic cells.
DESIGN:
In vitro study.
SETTING:
University hospital.
PATIENT(S):
Immortalized epithelial endometriotic cells.
INTERVENTION(S):
Treatment with the histone deacetylase inhibitor romidepsin or suberoylanilide hydroxamic acid (SAHA), or with the GPER antagonist G-15.
MAIN OUTCOME MEASURE(S):
Western blot analysis and quantitative real-time polymerase chain reaction (PCR) were used to monitor the expression of GPER in response to drug treatment. Effects of GPER stimulation and inhibition on cell proliferation were investigated by the 93-(4,5-dimethylthiazol-2-yl)2,5-diphenyl tetrazolium bromide (Sigma) (MTT) assay.
RESULT(S):
Our results demonstrate that romidepsin and SAHA reduce GPER expression in a concentration-dependent manner. This reduction correlated with the accumulation of acetylated histones. No decreased expression of the estrogen receptor (ER)-α and ERβ was found under comparable experimental conditions. Pretreatment of endometriotic cells with the GPER agonist G-1 stimulated cell proliferation accompanied by rapid Akt phosphorylation. G-15 reversed this stimulation and inhibited cell proliferation, which was accompanied by Akt dephosphorylation.
CONCLUSION(S):
G-protein-coupled estrogen receptor is proposed as a potential therapeutic target in endometriosis. The down-regulation of GPER and/or the impairment of its function may reduce the estrogen responsiveness in endometriosis, and therefore might be considered a possible treatment option of endometriosis.
AuthorsPatrick Imesch, Eleftherios P Samartzis, Konstantin J Dedes, Daniel Fink, André Fedier
JournalFertility and sterility (Fertil Steril) Vol. 100 Issue 3 Pg. 770-6 (Sep 2013) ISSN: 1556-5653 [Electronic] United States
PMID23755949 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
CopyrightCopyright © 2013 American Society for Reproductive Medicine. Published by Elsevier Inc. All rights reserved.
Chemical References
  • 4-(6-bromo-1,3-benzodioxol-5-yl)-3a,4,5,9b-3H-cyclopenta(c)quinoline
  • Benzodioxoles
  • Depsipeptides
  • ESR1 protein, human
  • Estrogen Receptor alpha
  • Estrogen Receptor beta
  • GPER1 protein, human
  • Histone Deacetylase Inhibitors
  • Hydroxamic Acids
  • Quinolines
  • Receptors, Estrogen
  • Receptors, G-Protein-Coupled
  • Vorinostat
  • romidepsin
Topics
  • Benzodioxoles (pharmacology, therapeutic use)
  • Cell Line, Transformed
  • Cell Proliferation (drug effects)
  • Depsipeptides (pharmacology, therapeutic use)
  • Down-Regulation (drug effects, genetics)
  • Drug Evaluation, Preclinical
  • Endometriosis (drug therapy, pathology)
  • Endometrium (drug effects, pathology)
  • Estrogen Receptor alpha (genetics, metabolism)
  • Estrogen Receptor beta (genetics, metabolism)
  • Female
  • Gene Expression Regulation (drug effects)
  • Histone Deacetylase Inhibitors (pharmacology)
  • Humans
  • Hydroxamic Acids (pharmacology, therapeutic use)
  • Quinolines (pharmacology, therapeutic use)
  • Receptors, Estrogen (antagonists & inhibitors, genetics, metabolism)
  • Receptors, G-Protein-Coupled (antagonists & inhibitors, genetics, metabolism)
  • Vorinostat

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: